Skip to main content

Table 4 Multivariable analysis for progression-free and overall survival (<70 and ≥70 years)a

From: Systemic therapy in younger and elderly patients with advanced biliary cancer: sub-analysis of ABC-02 and twelve other prospective trials

  Covariate PFS
<70 years
PFS
≥70 years
OS
<70 years
OS
≥70 years
Gender (reference; female) Female vs Male HR 1.00 (95% CI 0.84–1.18, P = 0.98) HR 1.14 (95% CI 0.83–1.56, P = 0.42) HR 1.12 (95% CI 0.94–1.33, P = 0.22) HR 1.33 (95% CI 0.97–1.84, P = 0.08)
ECOG performance status (reference; 0) 0 vs 1 HR 1.10 (95% CI 0.92–1.32) HR 0.86 (95% CI 0.60–1.24) HR 1.08 (95% CI 0.90–1.31) HR 0.81 (95% CI 0.57–1.16)
0 vs 2 HR 1.58 (95% CI 1.13–2.20)
[P = 0.04]
HR 1.03 (95% CI 0.58–1.83)
[P = 0.65]
HR 2.02 (95% CI 1.45–2.82)
[P = 0.001]
HR 1.84 (95% CI 1.03–3.28)
[P = 0.02]
Disease stage (reference; locally advanced) Locally advanced vs Metastatic HR 1.46 (95% CI 1.20–1.78, P < 0.001) HR 1.21 (95% CI 0.86–1.69, P = 0.28) HR 1.48 (95% CI 1.20–1.82, P < 0.001) HR 1.49 (95% CI 1.05–2.12, P = 0.03)
  1. PFS rogression-free survival, OSO verall survival, ECOG PS Eastern Cooperative Oncology Group Performance Status
  2. aThe multivariable model was adjusted for the following variables; treatment, haemoglobin, white blood cell count, neutrophil count, and bilirubin